Download PDF
Semin Liver Dis 2003; 23(1): 021-038
DOI: 10.1055/s-2003-37586
Copyright © 2002 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Immune Responses in Hepatitis B Virus Infection

Barbara Rehermann
  • Investigator, Liver Diseases Section, NIDDK, National Institutes of Health, HHS, Bethesda, Maryland
Further Information

Publication History

Publication Date:
03 March 2003 (online)

    Permissions and Reprints

ABSTRACT

Hepatitis B virus infection is one of the most frequent causes of chronic liver disease worldwide. Even though a preventive vaccine is available, the search for a cure for chronically infected patients remains a high priority to reduce the morbidity and mortality from liver cirrhosis and hepatocellular carcinoma. This review summarizes the immune response in acute, self-limited and chronic hepatitis B; its differential effects on viral replication and liver injury; and prospects for immunotherapy.

KEYWORDS

Liver - hepatitis B virus - T cell - immune response - cytokine

REFERENCES

  • 1 Beasley R P, Lin C-C, Hwang L Y, Chen C-S. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22,707 men in Taiwan.  Lancet . 1981;  2 1129-1133
    PubMedGoogle Scholar
  • 2 Ishikawa R, Biron C A. IFN induction and associated changes in splenic leukocyte distribution.  J Immunol . 1993;  150 3713-3727
    PubMedGoogle Scholar
  • 3 Vilcek J SG. Interferons and other cytokines. In: Fields BNKD, Howley PM, eds. Fundamental Virology, Vol 11 Philadelphia: Lippincott-Raven 1996: 341-365
    Google Scholar
  • 4 Salazar-Mather T P, Lewis C A, Biron C A. Type I interferons regulate inflammatory cell trafficking and macrophage inflammatory protein 1alpha delivery to the liver.  J Clin Invest . 2002;  110 321-330
    CrossrefPubMedGoogle Scholar
  • 5 Webster G J, Reignat S, Maini M K. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms.  Hepatology . 2000;  32 1117-1124
    CrossrefPubMedGoogle Scholar
  • 6 Lanier L L. NK cell receptors.  Annu Rev Immunol . 1998;  16 359-393
    CrossrefPubMedGoogle Scholar
  • 7 Salazar-Mather T P, Ishikawa R, Biron C A. NK cell trafficking and cytokine expression in splenic compartments after IFN induction and viral infection.  J Immunol . 1996;  157 3054-3064
    PubMedGoogle Scholar
  • 8 Bendelac A, Lantz O, Quimby M E. CD1 recognition by mouse NK1+ T lymphocytes.  Science . 1995;  268 863-865
    CrossrefPubMedGoogle Scholar
  • 9 Kawano T, Cui J, Koezuka Y. CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides.  Science . 1997;  278 1626-1629
    CrossrefPubMedGoogle Scholar
  • 10 Kakimi K, Lane T E, Chisari F V, Guidotti L G. Cutting edge: inhibition of hepatitis B virus replication by activated NK T cells does not require inflammatory cell recruitment to the liver.  J Immunol . 2001;  167 6701-6705
    PubMedGoogle Scholar
  • 11 Kakimi K, Guidotti L G, Koezuka Y, Chisari F V. Natural killer T cell activation inhibits hepatitis B virus replication in vivo.  J Exp Med . 2000;  192 921-930
    CrossrefPubMedGoogle Scholar
  • 12 Carnaud C, Lee D, Donnars O. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells.  J Immunol . 1999;  163 4647-4650
    PubMedGoogle Scholar
  • 13 Hayakawa Y, Takeda K, Yagita H. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide.  Eur J Immunol . 2001;  31 1720-1727
    CrossrefPubMedGoogle Scholar
  • 14 Eberl G, MacDonald H R. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells.  Eur J Immunol . 2000;  30 985-992
    CrossrefPubMedGoogle Scholar
  • 15 Baron J L, Gardiner L, Nishimura S. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection.  Immunity . 2002;  16 583-594
    CrossrefPubMedGoogle Scholar
  • 16 Pasquetto V, Guidotti L G, Kakimi K, Tsuji M, Chisari F V. Host-virus interactions during malaria infection in hepatitis B virus transgenic mice.  J Exp Med . 2000;  192 529-536
    CrossrefPubMedGoogle Scholar
  • 17 Thomson A. The Cytokine Handbook.  San Diego: Academic Press 1998
    Google Scholar
  • 18 Brunetto M, Stemler M, Bonino F. A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B.  J Hepatol . 1990;  10 258-261
    PubMedGoogle Scholar
  • 19 Hasegawa K, Huang J, Wands J. Association of hepatitis B viral precore mutants with fulminant hepatitis in Japan.  Virology . 1991;  185 460-463
    CrossrefPubMedGoogle Scholar
  • 20 Liang T J, Hasegawa K, Riman N, Wands J R, Ben-Porath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis.  N Engl J Med . 1991;  324 1705-1709
    PubMedGoogle Scholar
  • 21 Okamoto H, Yotsumoto S, Akahane Y. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen.  J Virol . 1990;  64 1298-1303
    PubMedGoogle Scholar
  • 22 Milich D R, McLachlan A. The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen.  Science . 1986;  234 1398-1401
    PubMedGoogle Scholar
  • 23 Schirmbeck R, Melber K, Kuhröber A, Janowicz Z A, Reimann J. Immunization with soluble hepatitis B virus surface protein elicits murine H-2 class I-restricted CD8+ cytotoxic T lymphocyte responses in vivo.  J Immunol . 1994;  152 1110-1119
    PubMedGoogle Scholar
  • 24 Sigal L J, Crotty S, Andino R, Rock K L. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen.  Nature . 1999;  398 77-80
    CrossrefPubMedGoogle Scholar
  • 25 Ridge J P, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell.  Nature . 1998;  393 474-478
    CrossrefPubMedGoogle Scholar
  • 26 Guidotti L G, Rochford R, Chung J. Viral clearance without destruction of infected cells during acute HBV infection.  Science . 1999;  284 825-829
    CrossrefPubMedGoogle Scholar
  • 27 Pavic I, Polic B, Crnkovic I. Participation of endogenous tumour necrosis factor alpha in host resistance to cytomegalovirus infection.  J Gen Virol . 1993;  74 2215-2223
    PubMedGoogle Scholar
  • 28 Franco M A, Tin C, Rott L S. Evidence for CD8+ T-cell immunity to murine rotavirus in the absence of perforin, fas, and gamma interferon.  J Virol . 1997;  71 479-486
    PubMedGoogle Scholar
  • 29 Franco A, Guidotti L G, Hobbs M V, Pasquetto V, Chisari F V. Pathogenetic effector function of CD4-positive T helper 1 cells in hepatitis B virus transgenic mice.  J Immunol . 1997;  159 2001-2008
    PubMedGoogle Scholar
  • 30 Maini M K, Boni C, Ogg G S. Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection.  Gastroenterology . 1999;  117 1386-1396
    PubMedGoogle Scholar
  • 31 Rehermann B, Fowler P, Sidney J. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis.  J Exp Med . 1995;  181 1047-1058
    CrossrefPubMedGoogle Scholar
  • 32 Bertoletti A, Ferrari C, Fiaccadori F. HLA class-I restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen.  Proc Natl Acad Sci U S A . 1991;  88 10445-10449
    PubMedGoogle Scholar
  • 33 Ferrari C, Bertoletti A, Penna A. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen.  J Clin Invest . 1991;  88 214-222
    PubMedGoogle Scholar
  • 34 Penna A, Fowler P, Bertoletti A. Hepatitis B virus (HBV)-specific cytotoxic T-cell (CTL) response in humans: characterization of HLA class II-restricted CTLs that recognize endogenously synthesized HBV envelope antigens.  J Virol . 1992;  66 1193-1198
    PubMedGoogle Scholar
  • 35 Missale G, Redeker A, Person J. HLA-A31 and Aw68 restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis.  J Exp Med . 1993;  177 751-762
    CrossrefPubMedGoogle Scholar
  • 36 Nayersina R, Fowler P, Guilhot S. HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection.  J Immunol . 1993;  150 4659-4671
    PubMedGoogle Scholar
  • 37 Bertoletti A, Chisari F V, Penna A. Definition of a minimal optimal cytotoxic T cell epitope within the hepatitis B virus nucleocapsid protein.  J Virol . 1993;  67 2376-2380
    PubMedGoogle Scholar
  • 38 Sette A, Vitiello A, Rehermann B. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes.  J Immunol . 1994;  153 5586-5592
    PubMedGoogle Scholar
  • 39 Chisari F V, Ferrari C. Immunobiology and pathogenesis of viral hepatitis. In: Nathanson N, ed. Viral Pathogenesis Philadelphia: Lippincott-Raven 1997: 745-778
    Google Scholar
  • 40 Del Guercio F M, Sidney J, Hermanson G. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype.  J Immunol . 1995;  154 685-693
    PubMedGoogle Scholar
  • 41 Sidney J, Grey H M, Kubo R T, Sette A. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs.  Immunol Today . 1996;  17 261-266
    CrossrefPubMedGoogle Scholar
  • 42 Sidney J, Del Guercio F M, Southwood S. Several HLA alleles share overlapping peptide specificities.  J Immunol . 1995;  154 247-259
    PubMedGoogle Scholar
  • 43 Sidney J, Grey H M, Southwood S. Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules.  Hum Immunol . 1996;  45 79-93
    CrossrefPubMedGoogle Scholar
  • 44 Thursz M R, Thomas H C, Greenwood B M, Hill A V. Heterozygote advantage for HLA class-II type in hepatitis B virus infection.  Nat Genet . 1997;  17 11-12
    CrossrefPubMedGoogle Scholar
  • 45 Ishikawa T, Kono D, Chung J. Polyclonality and multispecificity of the CTL response to a single viral epitope.  J Immunol . 1998;  161 5842-5850
    PubMedGoogle Scholar
  • 46 Tuttleman J S, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells.  Cell . 1986;  47 451-460
    CrossrefPubMedGoogle Scholar
  • 47 Guidotti L G, Matzke B, Schaller H, Chisari F V. High-level hepatitis B virus replication in transgenic mice.  J Virol . 1995;  69 6158-6169
    PubMedGoogle Scholar
  • 48 Ando K, Guidotti L G, Wirth S. Class I restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo.  J Immunol . 1994;  152 3245-3253
    PubMedGoogle Scholar
  • 49 Pasquetto V, Wieland S, Chisari F V. Intracellular hepatitis B virus nucleocapsids survive cytotoxic T-lymphocyte- induced apoptosis.  J Virol . 2000;  74 9792-9796
    CrossrefPubMedGoogle Scholar
  • 50 McClary H, Koch R, Chisari F V, Guidotti L G. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines.  J Virol . 2000;  74 2255-2264
    CrossrefPubMedGoogle Scholar
  • 51 Guidotti L G, Ishikawa T, Hobbs M V. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes.  Immunity . 1996;  4 35-36
    PubMedGoogle Scholar
  • 52 Guidotti L G, Borrow P, Brown A. Noncytopathic clearance of lymphocytic choriomeningitis virus from the hepatocyte.  J Exp Med . 1999;  189 1555-1564
    CrossrefPubMedGoogle Scholar
  • 53 Guidotti L G, McClary H, Loudis J M, Chisari F V. Nitric oxide inhibits hepatitis B virus replication in the livers of transgenic mice.  J Exp Med . 2000;  191 1247-1252
    CrossrefPubMedGoogle Scholar
  • 54 Dong B, Silverman R H. Alternative function of a protein kinase homology domain in 2′,5′-oligoadenylate dependent RNase L.  Nucleic Acids Res . 1999;  27 439-445
    CrossrefPubMedGoogle Scholar
  • 55 Silverman R H. Fascination with 2-5A-dependent RNase: a unique enzyme that functions in interferon action.  J Interferon Res . 1994;  14 101-104
    PubMedGoogle Scholar
  • 56 Terenzi F, deVeer M J, Ying H. The antiviral enzymes PKR and RNase L suppress gene expression from viral and non-viral based vectors.  Nucleic Acids Res . 1999;  27 4369-4375
    CrossrefPubMedGoogle Scholar
  • 57 Haller O, Frese M, Kochs G. Mx proteins: mediators of innate resistance to RNA viruses.  Rev Sci Tech . 1998;  17 220-230
    PubMedGoogle Scholar
  • 58 Samuel C E. Reoviruses and the interferon system.  Curr Top Microbiol Immunol . 1998;  233 125-145
    PubMedGoogle Scholar
  • 59 Kalvakolanu D V, Borden E C. An overview of the interferon system: signal transduction and mechanisms of action.  Cancer Invest . 1996;  14 25-53
    PubMedGoogle Scholar
  • 60 Wieland S F, Guidotti L G, Chisari F V. Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice.  J Virol . 2000;  74 4165-4173
    CrossrefPubMedGoogle Scholar
  • 61 Tsui L V, Guidotti L G, Ishikawa T, Chisari F V. Post-transcriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte activated hepatocytes.  Proc Natl Acad Sci U S A . 1995;  92 12398-12402
    PubMedGoogle Scholar
  • 62 Heise T, Guidotti L G, Chisari F V. La autoantigen specifically recognizes a predicted stem-loop in hepatitis B virus RNA.  J Virol . 1999;  73 5767-5776
    PubMedGoogle Scholar
  • 63 Heise T, Guidotti L G, Cavanaugh V J, Chisari F V. Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice.  J Virol . 1999;  73 474-481
    PubMedGoogle Scholar
  • 64 Ando K, Moriyama T, Guidotti L G. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis.  J Exp Med . 1993;  178 1541-1554
    CrossrefPubMedGoogle Scholar
  • 65 Kakimi K, Lane T E, Wieland S. Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes.  J Exp Med . 2001;  194 1755-1766
    CrossrefPubMedGoogle Scholar
  • 66 Park J W, Gruys M E, McCormick K. Primary hepatocytes from mice treated with IL-2/IL-12 produce T cell chemoattractant activity that is dependent on monokine induced by IFN-gamma (Mig) and chemokine responsive to gamma-2 (Crg-2).  J Immunol . 2001;  166 3763-3770
    PubMedGoogle Scholar
  • 67 Taub D D, Conlon K, Lloyd A R, Oppenheim J J, Kelvin D J. Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta.  Science . 1993;  260 355-358
    PubMedGoogle Scholar
  • 68 Cook D N, Beck M A, Coffman T M. Requirement of MIP-1 alpha for an inflammatory response to viral infection.  Science . 1995;  269 1583-1585
    PubMedGoogle Scholar
  • 69 Shields P L, Morland C M, Salmon M. Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver.  J Immunol . 1999;  163 6236-6243
    PubMedGoogle Scholar
  • 70 Salazar-Mather T P, Orange J S, Biron C A. Early murine cytomegalovirus (MCMV) infection induces liver natural killer (NK) cell inflammation and protection through macrophage inflammatory protein 1alpha (MIP-1alpha)-dependent pathways.  J Exp Med . 1998;  187 1-14
    CrossrefPubMedGoogle Scholar
  • 71 Kaneko Y, Harada M, Kawano T. Augmentation of Valpha14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis.  J Exp Med . 2000;  191 105-114
    CrossrefPubMedGoogle Scholar
  • 72 Toyonaga T, Hino O, Sugai S. Chronic active hepatitis in transgenic mice expressing interferon-gamma in the liver.  Proc Natl Acad Sci U S A . 1994;  91 614-618
    PubMedGoogle Scholar
  • 73 Wang H, Gao X, Fukumoto S. Differential expression and regulation of chemokines JE, KC, and IP-10 gene in primary cultured murine hepatocytes.  J Cell Physiol . 1999;  181 361-370
    CrossrefPubMedGoogle Scholar
  • 74 Narumi S, Yoneyama H, Inadera H. TNF-alpha is a potent inducer for IFN-inducible protein-10 in hepatocytes and unaffected by GM-CSF in vivo, in contrast to IL-1beta and IFN-gamma.  Cytokine . 2000;  12 1007-1016
    CrossrefPubMedGoogle Scholar
  • 75 Bonecchi R, Bianchi G, Bordignon P P. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (TH1s) and TH2s.  J Exp Med . 1998;  187 129-134
    CrossrefPubMedGoogle Scholar
  • 76 Mehal W Z, Juedes A E, Crispe I N. Selective retention of activated CD8+ T cells by the normal liver.  J Immunol . 1999;  163 3202-3210
    CrossrefPubMedGoogle Scholar
  • 77 Diepolder H M, Jung M C, Wierenga E. Anergic TH1 clones specific for hepatitis B virus (HBV) core peptides are inhibitory to other HBV core-specific CD4+ T cells in vitro.  J Virol . 1996;  70 7540-7548
    PubMedGoogle Scholar
  • 78 Penna A, Artini M, Cavalli A. Long lasting memory T cell responses following self-limited acute hepatitis B.  J Clin Invest . 1996;  98 1185-1194
    PubMedGoogle Scholar
  • 79 Rehermann B, Ferrari C, Pasquinelli C, Chisari F V. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.  Nat Med . 1996;  2 1104-1108
    CrossrefPubMedGoogle Scholar
  • 80 Rehermann B, Lau D, Hoofnagle J, Chisari F V. Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection.  J Clin Invest . 1996;  97 1655-1665
    PubMedGoogle Scholar
  • 81 Chazouilleres O, Mamish D, Kim M. "Occult" hepatitis B virus as source of infection in liver transplant recipients.  Lancet . 1994;  343 142-146
    CrossrefPubMedGoogle Scholar
  • 82 Blum H E, Stowring L, Figus A. Detection of hepatitis B virus DNA in hepatocytes, bile duct epithelium and vascular elements by in situ hybridization.  Proc Natl Acad Sci U S A . 1983;  80 6682-6685
    PubMedGoogle Scholar
  • 83 Dejean A, Lugassy C, Zafrani S, Tiollais P, Brechot C. Detection of hepatitis B virus DNA in pancreas, kidney and skin of two human carriers of the virus.  J Gen Virol . 1984;  65 651-655
    PubMedGoogle Scholar
  • 84 Yoffe B, Burns D K, Bhatt H S, Combes B. Extrahepatic hepatitis B virus DNA sequences in patients with acute hepatitis B infection.  Hepatology . 1990;  12 187-192
    PubMedGoogle Scholar
  • 85 Beasley R P, Hwang L Y, Stevens C E. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial.  Hepatology . 1993;  3 135-141
    PubMedGoogle Scholar
  • 86 Ando K, Guidotti L G, Cerny A, Ishikawa T, Chisari F V. Access to antigen restricts cytotoxic T lymphocyte function in vivo.  J Immunol . 1994;  153 482-489
    PubMedGoogle Scholar
  • 87 Bertoletti A, Constanzo A, Chisari F V. Cytotoxic T lymphocyte response to a wild-type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope.  J Exp Med . 1994;  180 933-943
    CrossrefPubMedGoogle Scholar
  • 88 Bertoletti A, D'Elios M M, Boni C. Different cytokine profiles of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infections.  Gastroenterology . 1997;  112 193-199
    PubMedGoogle Scholar
  • 89 Valitutti S, Müller S, Dessing M, Lanzavecchia A. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy.  J Exp Med . 1996;  183 1917-1921
    CrossrefPubMedGoogle Scholar
  • 90 Chisari F V. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B.  Am J Pathol . 2000;  156 1117-1132
    PubMedGoogle Scholar
  • 91 Bertoletti A, Sette A, Chisari F V. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells.  Nature . 1994;  369 407-410
    CrossrefPubMedGoogle Scholar
  • 92 Klenerman P, Rowland-Jones S, McAdams S. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants.  Nature . 1994;  369 403-407
    CrossrefPubMedGoogle Scholar
  • 93 Borrow P, Wei X, Horwitz M S. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus.  Nat Med . 1997;  3 212-217
    CrossrefPubMedGoogle Scholar
  • 94 Chang K M, Rehermann B, McHutchison J G. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus.  J Clin Invest . 1997;  100 2376-2385
    CrossrefPubMedGoogle Scholar
  • 95 Kaneko T, Moriyama T, Udaka K. Impaired induction of cytotoxic T lymphocytes by antagonism of a weak agonist borne by a variant hepatitis C virus epitope.  Eur J Immunol . 1997;  27 1782-1787
    PubMedGoogle Scholar
  • 96 Goulder P J, Phillips R E, Colbert R A. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS.  Nat Med . 1997;  3 212-217
    CrossrefPubMedGoogle Scholar
  • 97 Niewiesk S, Daenke S, Parker C E. Naturally occurring variants of human T-cell leukemia virus type I Tax protein impair its recognition by cytotoxic T lymphocytes and the transactivation function of Tax.  J Virol . 1995;  69 2649-2653
    PubMedGoogle Scholar
  • 98 Lanzavecchia A. Understanding the mechanisms of sustained signaling and T cell activation.  J Exp Med . 1997;  185 1717-1719
    CrossrefPubMedGoogle Scholar
  • 99 Evavold B D, Allen P M. Separation of IL-4 production from Th cell proliferation by an altered T cell receptor ligand.  Science . 1991;  252 1308-1310
    PubMedGoogle Scholar
  • 100 Sloan-Lancaster J, Evavold B, Allen P. Induction of T-cell anergy by altered T-cell-receptor ligand.  Nature . 1993;  363 156-159
    CrossrefPubMedGoogle Scholar
  • 101 Milich D R. T- and B-cell recognition of hepatitis B viral antigens.  Immunol Today . 1988;  9 380-386
    CrossrefPubMedGoogle Scholar
  • 102 Milich D R, Jones J E, Hughes J L. Is it a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero?.  Proc Natl Acad Sci U S A . 1990;  87 6599-6603
    PubMedGoogle Scholar
  • 103 Reifenberg K, Deutschle T, Wild J. The hepatitis B virus e antigen cannot pass the murine placenta efficiently and does not induce CTL immune tolerance in H-2b mice in utero.  Virology . 1998;  243 45-53
    CrossrefPubMedGoogle Scholar
  • 104 Merkle H, Deutschle T, Gastrock-Balitsch I. H-2(d) mice born to and reared by HBeAg-transgenic mothers do not develop T cell tolerance toward the hepatitis B virus core gene products.  Virology . 2000;  273 149-159
    CrossrefPubMedGoogle Scholar
  • 105 Cote P J, Toshkov I, Bellezza C. Temporal pathogenesis of experimental neonatal woodchuck hepatitis virus infection: increased initial viral load and decreased severity of acute hepatitis during the development of chronic viral infection.  Hepatology . 2000;  32 807-817
    CrossrefPubMedGoogle Scholar
  • 106 Nakamura I, Nupp J T, Cowlen M. Pathogenesis of experimental neonatal woodchuck hepatitis virus infection: chronicity as an outcome of infection is associated with a diminished acute hepatitis that is temporally deficient for the expression of interferon gamma and tumor necrosis factor-alpha messenger RNAs.  Hepatology . 2001;  33 439-447
    CrossrefPubMedGoogle Scholar
  • 107 Barnaba V, Franco A, Alberti A. Recognition of hepatitis B envelope proteins by liver-infiltrating T lymphocytes in chronic HBV infection.  J Immunol . 1989;  143 2650-2655
    PubMedGoogle Scholar
  • 108 Ferrari C, Penna A, Giuberti T. Intrahepatic, nucleocapsid antigen-specific T cells in chronic active hepatitis B.  J Immunol . 1987;  139 2050-2058
    PubMedGoogle Scholar
  • 109 Badardin K A, Desmet V J. Interdigitating and dendritic reticulum cells in chronic active hepatitis.  Histopathology . 1984;  8 657-667
    CrossrefPubMedGoogle Scholar
  • 110 Hoofnagle J H, Shafritz D A, Popper H. Chronic type B hepatitis and the "healthy" HBsAg carrier state.  Hepatology . 1987;  7 758-763
    PubMedGoogle Scholar
  • 111 Tsai S L, Chen M Y, Lai M Y. Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens.  J Clin Invest . 1992;  89 87-96
    PubMedGoogle Scholar
  • 112 Maini M K, Boni C, Lee C K. The role of virus-specific CD8+ cells in liver damage and viral control during persistent hepatitis B virus (HBV) infection.  J Exp Med . 2000;  191 1269-1280
    CrossrefPubMedGoogle Scholar
  • 113 Mita E, Hayashi N, Iio S. Role of Fas ligand in apoptosis induced by hepatitis C virus infection.  Biochem Biophys Res Commun . 1994;  204 468-474
    CrossrefPubMedGoogle Scholar
  • 114 Lohman B L, Razvi E S, Welsh R M. T-lymphocyte downregulation after acute viral infection is not dependent on CD95 (Fas) receptor-ligand interactions.  J Virol . 1996;  70 8199-8203
    PubMedGoogle Scholar
  • 115 Vassalli P. The pathophysiology of tumor necrosis factors.  Annu Rev Immunol . 1992;  10 411-452
    CrossrefPubMedGoogle Scholar
  • 116 Koziel M J, Dudley D, Afdhal N. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release.  J Clin Invest . 1995;  96 2311-2321
    PubMedGoogle Scholar
  • 117 Kinkhabwala M, Sehajpal P, Skolnik E. A novel addition to the T cell repertory: cell surface expression of tumor necrosis factor/cachectin by activated normal human T cells.  J Exp Med . 1990;  171 941-946
    CrossrefPubMedGoogle Scholar
  • 118 Ganchi P A, Sun S C, Greene W C, Ballard D W. I kappa B/MAD-3 masks the nuclear localization signal of NF-kappa B p65 and requires the transactivation domain to inhibit NF-kappa B p65 DNA binding.  Mol Biol Cell . 1992;  3 13391352
    PubMedGoogle Scholar
  • 119 Grilli M, Chiu J J, Lenardo M J. NF-kappa B and Rel: participants in a multiform transcriptional regulatory system.  Int Rev Cytol . 1993;  143 1-62
    PubMedGoogle Scholar
  • 120 Beg A A, Ruben S M, Scheinman R I. I kappa B interacts with the nuclear localization sequences of the subunits of NF-kappa B: a mechanism for cytoplasmic retention [published erratum appears in Genes Dev 1992;6:2664-2665].  Genes Dev . 1992;  6 1899-1913
    PubMedGoogle Scholar
  • 121 Su F, Schneider R J. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha.  Proc Natl Acad Sci U S A . 1997;  94 8744-8749
    CrossrefPubMedGoogle Scholar
  • 122 Huang S N, Chisari F V. Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice.  Hepatology . 1995;  21 620-626
    CrossrefPubMedGoogle Scholar
  • 123 Chisari F V, Filippi P, Buras J. Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice.  Proc Natl Acad Sci U S A . 1987;  84 6909-6913
    PubMedGoogle Scholar
  • 124 Chisari F V, Klopchin K, Moriyama T. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice.  Cell . 1989;  59 1145-1156
    CrossrefPubMedGoogle Scholar
  • 125 Larkin J, Clayton M, Sun B. Hepatitis B virus transgenic mouse model of chronic liver disease.  Nat Med . 1999;  5 907-912
    PubMedGoogle Scholar
  • 126 Nakamoto Y, Guidotti L G, Kuhlen C V, Fowler P, Chisari F V. Immune pathogenesis of hepatocellular carcinoma.  J Exp Med . 1998;  188 341-350
    CrossrefPubMedGoogle Scholar
  • 127 Gallimore A, Glithero A, Godkin A. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes.  J Exp Med . 1998;  187 1383-1393
    CrossrefPubMedGoogle Scholar
  • 128 Zajac A J, Blattman J N, Murali-Krishna K. Viral immune evasion due to persistence of activated T cells without effector function.  J Exp Med . 1998;  188 2205-2213
    CrossrefPubMedGoogle Scholar
  • 129 Boni C, Bertoletti A, Penna A. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.  J Clin Invest . 1998;  102 968-975
    PubMedGoogle Scholar
  • 130 Boni C, Penna A, Ogg G S. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.  Hepatology . 2001;  33 963-971
    CrossrefPubMedGoogle Scholar
  • 131 Marinos G, Naoumov N V, Williams R. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection.  Hepatology . 1996;  24 991-995
    PubMedGoogle Scholar
  • 132 Lau G K, Suri D, Liang R. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen.  Gastroenterology . 2002;  122 614-624
    CrossrefPubMedGoogle Scholar
  • 133 Ilan Y, Nagler A, Adler R. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor.  Gastroenterology . 1993;  104 1818-1821
    PubMedGoogle Scholar
  • 134 Jung M-C, Diepolder H M, Spengler U. Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection.  J Virol . 1995;  69 3358-3368
    PubMedGoogle Scholar
  • 135 Ferrari C, Penna A, Bertoletti A. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection.  J Immunol . 1990;  145 3442-3449
    PubMedGoogle Scholar
  • 136 Milich D R, McLachlan A, Thornton G B, Hughes J L. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site.  Nature . 1987;  329 547-549
    CrossrefPubMedGoogle Scholar
  • 137 Kakimi K, Isogawa M, Chung J, Sette A, Chisari F V. Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections.  J Virol . 2002;  76 8609-8620
    CrossrefPubMedGoogle Scholar
  • 138 Gallimore A, Dumrese T, Hengartner H, Zinkernagel R M, Rammensee H G. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides.  J Exp Med . 1998;  187 1647-1657
    CrossrefPubMedGoogle Scholar
  • 139 Geginat G, Ruppert T, Hengel H, Holtappels R, Koszinowski U H. IFN-gamma is a prerequisite for optimal antigen processing of viral peptides in vivo.  J Immunol . 1997;  158 3303-3310
    PubMedGoogle Scholar
  • 140 Sijts A A M J, Ruppert T, Rehermann B. Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes.  J Exp Med . 2000;  191 503-514
    CrossrefPubMedGoogle Scholar
  • 141 Vitiello A, Ishioka G, Grey H M. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. 1. Induction of a primary cytotoxic T lymphocyte response in humans.  J Clin Invest . 1995;  95 341-349
    PubMedGoogle Scholar
  • 142 Livingston B D, Crimi C, Grey H. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection.  J Immunol . 1997;  159 1383-1392
    PubMedGoogle Scholar
  • 143 Couillin I, Pol S, Mancini M. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens.  J Infect Dis . 1999;  180 15-26
    CrossrefPubMedGoogle Scholar
  • 144 Ulmer J B, Donnelly J J, Parker S E. Heterologous protection against influenza by injection of DNA encoding a viral protein.  Science . 1993;  259 1745-1749
    PubMedGoogle Scholar
  • 145 Wang B, Boyer J, Srikantan V. DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type 1 in mice and nonhuman primates.  DNA Cell Biol . 1993;  12 799-805
    PubMedGoogle Scholar
  • 146 Wang B, Ugen K E, Srikantan V. Gene inoculation generates immune responses against human immunodeficiency virus type 1.  Proc Natl Acad Sci U S A . 1993;  980 4156-4160
    PubMedGoogle Scholar
  • 147 Xiang Z Q, Spitalnick S, Tran M. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus.  Virology . 1994;  199 132-140
    CrossrefPubMedGoogle Scholar
  • 148 Michel M L, Davis H L, Schleef M. DNA-mediated immunization to the hepatitis B surface antigen in mice: aspects of the humoral response mimic hepatitis B viral infection in humans.  Proc Natl Acad Sci U S A . 1995;  92 5307-5311
    PubMedGoogle Scholar
  • 149 Mancini M, Hadchouel M, Tiollais P, Pourcel C, Michel M L. Induction of anti-hepatitis B surface antigen (HBsAg) antibodies in HBsAg producing transgenic mice: a possible way of circumventing "nonresponse" to HBsAg.  J Med Virol . 1993;  39 67-74
    PubMedGoogle Scholar
  • 150 Mancini M, Hadchouel M, Davis H L. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state.  Proc Natl Acad Sci U S A . 1996;  93 12496-12501
    CrossrefPubMedGoogle Scholar
  • 151 Shimizu Y, Guidotti L G, Fowler P, Chisari F V. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice.  J Immunol . 1998;  161 4520-4529
    PubMedGoogle Scholar
  • 152 Wirth S, Guidotti L G, Ando K, Schlicht H J, Chisari F V. Breaking tolerance leads to autoantibody production but not autoimmune liver disease in hepatitis B virus envelope transgenic mice.  J Immunol . 1995;  154 2504-2515
    PubMedGoogle Scholar
  • 153 Pancholi P, Lee D H, Liu Q. DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee.  Hepatology . 2001;  33 448-454
    CrossrefPubMedGoogle Scholar
  • 154 Tamaru M, Nishioji K, Kobayashi Y. Liver-infiltrating T lymphocytes are attracted selectively by IFN-inducible protein-10.  Cytokine . 2000;  12 299-308
    CrossrefPubMedGoogle Scholar
  • 155 Murai M, Yoneyama H, Harada A. Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease.  J Clin Invest . 1999;  104 49-57
    PubMedGoogle Scholar
  • 156 Lin M T, Hinton D R, Stohlman S A. Mechanisms of viral clearance in perforin-deficient mice.  Adv Exp Med Biol . 1998;  440 431-436
    PubMedGoogle Scholar
  • 157 Parra B, Hinton D R, Marten N W. IFN-gamma is required for viral clearance from central nervous system oligodendroglia.  J Immunol . 1999;  162 1641-1647
    PubMedGoogle Scholar
  • 158 Gebhard J R, Perry C M, Harkins S. Coxsackievirus B3-induced myocarditis: perforin exacerbates disease, but plays no detectable role in virus clearance.  Am J Pathol . 1998;  153 417-428
    PubMedGoogle Scholar
  • 159 Horwitz M S, Krahl T, Fine C, Lee J, Sarvetnick N. Protection from lethal coxsackievirus-induced pancreatitis by expression of gamma interferon.  J Virol . 1999;  73 1756-1766
    PubMedGoogle Scholar
  • 160 Benihoud K, Saggio I, Opolon P. Efficient, repeated adenovirus-mediated gene transfer in mice lacking both tumor necrosis factor alpha and lymphotoxin alpha.  J Virol . 1998;  72 9514-9525
    PubMedGoogle Scholar
  • 161 Tay C H, Welsh R M. Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells.  J Virol . 1997;  71 267-275
    PubMedGoogle Scholar
  • 162 Kagi D, Ledermann B, Burki K. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice.  Nature . 1994;  369 31-37
    CrossrefPubMedGoogle Scholar
  • 163 Cavanaugh V J, Guidotti L G, Chisari F V. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice.  J Virol . 1997;  71 3236-3243
    PubMedGoogle Scholar
  • 164 Gilles P N, Fey G, Chisari F V. Tumor necrosis factor-alpha negatively regulates hepatitis B virus gene expression in transgenic mice.  J Virol . 1992;  66 3955-3960
    PubMedGoogle Scholar
  • 165 Guidotti L G, Guilhot S, Chisari F V. Interleukin 2 and interferon alpha/beta downregulate hepatitis B virus gene expression in vivo by tumor necrosis factor dependent and independent pathways.  J Virol . 1994;  68 1265-1270
    PubMedGoogle Scholar
  • 166 Cavanaugh V J, Guidotti L G, Chisari F V. Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice.  J Virol . 1998;  72 2630-2637
    PubMedGoogle Scholar
  • 167 Guidotti L G, Borrow P, Hobbs M V. Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver.  Proc Natl Acad Sci U S A . 1996;  93 4589-4594
    CrossrefPubMedGoogle Scholar
  • 168 Davis G L, Hoofnagle J H, Waggoner J G. Acute type A hepatitis during chronic hepatitis B virus infection: association of depressed hepatitis B virus replication with appearance of endogenous alpha interferon.  J Med Virol . 1984;  14 141-147
    PubMedGoogle Scholar
  • 169 Sheen I S, Liaw Y F, Lin D Y, Chu C M. Role of hepatitis C and delta viruses in the termination of chronic hepatitis B surface antigen carrier state: a multivariate analysis in a longitudinal follow-up study.  J Infect Dis . 1994;  170 358-361
    PubMedGoogle Scholar
  • 170 Michalak T I, Pasquinelli C, Guilhot S, Chisari F V. Hepatitis B virus persistence after recovery from acute viral hepatitis.  J Clin Invest . 1994;  93 230-239
    PubMedGoogle Scholar
  • 171 Niewiesk S, Daenke S, Parker C. The transactivator gene of human T-cell leukemia virus type I is more variable within and between healthy carriers than patients with tropical spastic paraparesis.  J Virol . 1994;  68 6778-6781
    PubMedGoogle Scholar
  • 172 Tan L C, Gudgeon N, Annels N E. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers.  J Immunol . 1999;  162 1827-1835
    PubMedGoogle Scholar
  • 173 Liu T, Khanna K M, Chen X, Fink D J, Hendricks R L. CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons.  J Exp Med . 2000;  191 1459-1466
    CrossrefPubMedGoogle Scholar
  • 174 Ciurea A, Klenerman P, Hunziker L. Persistence of lymphocytic choriomeningitis virus at very low levels in immune mice.  Proc Natl Acad Sci U S A . 1999;  96 11964-11969
    CrossrefPubMedGoogle Scholar
      >